This COVID Biotech Stock Soars 253% this week. That’s right, this little-known COVID biotech stock, Claritas Pharmaceuticals (formerly Kalytera Therapeutics) (KALTD) was ranked #1 by CanninBot this week. But what happened to Claritas Pharmaceuticals this week?
Related: Little-known Biotech Stock Up 149%
Earlier this week, CanninBot discovered a profitable trade opportunity with San Rafael, CA-based Claritas Pharmaceuticals. Today, the stock was valued at $0.39/share for an impressive 253% return in 5 days!
What is Claritas Pharmaceuticals?
Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains. The company’s scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine.
Related: Hemp Stock HMPQ Soars 123%
Claritas scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Their expertise and professional network enable them to create groundbreaking opportunities that tackle drug development challenges.
What is this COVID Biotech Stock Developing to Fight the Disease?
R-107 was designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. This drug releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. Without a functional spike protein, the virus is rendered harmless due to its inability to enter and infect cells. Vaccines may fail when new mutations in the spike protein arise, but R-107 and the nitric oxide payload that it delivers will continue to render the virus harmless–regardless of how it may mutate.
What is CanninBot?
After rigorous development and backtesting over the last 3 years, we are proud to offer CanninBot to the public. CanninBot is a proprietary machine learning software that evaluates 450 cannabis stocks daily based on the 10 best technical indicators.
CanninBot members receive daily alerts with a ranking for the 20 strongest stocks, for that specific day, allowing the best opportunity to make serious potential gains on stocks like Claritas Pharmaceuticals. Interested? Get your free week now.
Who are the Experts Behind Cannin.com?
Cannin.com has a global team of traders, analysts, software engineers, and cannabis industry veterans to provide the tools and information for our members to capitalize on this rapidly growing industry. In fact, our team continues to identify profitable trade opportunities every week.
We’re proud to say that 78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the last 3 years.
COVID Biotech Stock Soars 253% this Week
Cannin Investment Group: Your Hemp Stocks Experts
Cannin.com is your trusted resource for top hemp stocks. Our team of financial experts evaluates all emerging hemp stock investing opportunities. We aggregate hundreds of hours of market research to provide tips on the best hemp stocks for 2021.
Use Cannin as your resource for:
Is it too late to invest in hemp stocks? No! This is the perfect time to invest.
Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now.
Are you looking to buy stock in hemp companies or stock in cannabis companies in 2021? Interested in penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks? We can help.
Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best hemp stocks – we’ll show you how at cannin.com.